PDE5A and heart failure: The Phosphodiesterase-5 (PDE-5)Inhibition to Improve Clinical Status and Exercise Capacity in Heart Failure withPreserved Ejection Fraction (RELAX) trial tested the hypothesis that therapy withthe PDE-5 inhibitor sildenafil would improve exercise capacity in HFpEF assessedby the change in peak oxygen consumption [152].